Quick Answer
Esperion Therapeutics, Inc. reported Total Revenue of $403.14 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +21.3% in Total Revenue from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $145.42 million | Q2 2019: $982.0 thousand | Q3 2019: $981.0 thousand | Q4 2019: $982.0 thousand | Q1 2020: $1.84 million | Q2 2020: $212.24 million | Q3 2020: $3.83 million | Q4 2020: $9.64 million | Q1 2021: $7.98 million | Q2 2021: $40.66 million | Q3 2021: $14.41 million | Q1 2022: $18.84 million | Q2 2022: $18.84 million | Q3 2022: $18.98 million | Q1 2023: $24.33 million | Q2 2023: $25.79 million | Q3 2023: $33.97 million | Q1 2024: $137.74 million | Q2 2024: $73.83 million | Q3 2024: $51.63 million | Q1 2025: $65.00 million | Q2 2025: $82.39 million | Q3 2025: $87.31 million.
- Historical annual values: Fiscal year 2025: $403.14 million | Fiscal year 2024: $332.31 million | Fiscal year 2023: $116.33 million | Fiscal year 2022: $75.48 million | Fiscal year 2021: $78.45 million | Fiscal year 2020: $227.55 million | Fiscal year 2019: $148.36 million | Fiscal year 2018: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: